{"id":2262,"date":"2017-04-07T00:00:00","date_gmt":"2017-04-07T00:00:00","guid":{"rendered":"http:\/\/www.pharma-mkting.comindex.php\/2017\/04\/07\/pinup040717\/"},"modified":"2019-02-06T02:14:39","modified_gmt":"2019-02-06T02:14:39","slug":"pinup040717","status":"publish","type":"post","link":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/articles\/news\/pinup040717\/","title":{"rendered":"PinUp: Dr. Scott Gottlieb Answers Questions About Drug Safety, Speeding FDA’s Drug Approval Process, and the Opioid Epidemic at His Senate Conformation Hearing, more…"},"content":{"rendered":"

Pharma Industry News Update<\/b>: 7 April 2017<\/p>\n\n

Gottlieb’s Views on Drug Safety Versus Speed to Market In this 3.5-minute audio snippet, Pharmaguy summarizes the testimony of Dr. Scott Gottlieb, president Trump’s nominee to head the FDA, before the U.S. Senate Committee on Health, Education, Labor and Pensions. In particular, where’s the balance between drug safety and speeding up clinical trials to bring drugs to market faster?<\/p>\n

Senator Warren Goes After Gottlieb Regarding Drug Safety<\/p>\n

From www.pharma-mkting.com<\/p>\n

At his April 5, 2017, Senate confirmation hearing, Dr. Scott Gottlieb, President Trump’s nominee for FDA Commissioner, responded to Massachusetts Senator Elizabeth Warren’s concern about his commitment to FDA’s basic safety mission.<\/p>\n

Senator Warren cited Gottlieb’s comments about how the thalidomide episode had a lasting effect on the FDA’s work. The comments appeared in a 2012 article titled “Changing the FDA’s Culture.”<\/p>\n

In that article, Gottlieb said “In so heavily prioritizing one of its obligations – the protection of consumers – the FDA has sometimes subordinated and neglected its other key obligation, which is to guide new medical innovations to market.”<\/p>\n

More here…<\/a><\/p>\n

Further Reading & Listening:<\/b><\/p>\n